

Congrès 2022

Présentation orale	Bone mineral density in men with de novo metastatic castration sensitive prostate cancer treated with or without abiraterone plus prednisone in the PEACE-1 phase 3 trial.	Guilhem Roubaud, Marie Kostine, Raymond S. McDermott, Alice Bernard-Tessier, Xavier Maldonado, Marlon Silva, Aude Fléchon, Dominik R. Berthold, Philippe Ronchin, Bertrand F Tombal, Loïc Mourey, Gwenaëlle Gravis, Anne Escande, Sophie Abadie-Lacourtoisie, Antoine Thiery-Vuillemin, Miguel A Climent, Héléne Ribault, Alberto Bossi, Stéphanie Foulon, Karim Fizazi	ASCO GU
Poster	CIMUC : Chemotherapy following Immune checkpoint inhibitors in patients with locally advanced or Metastatic Urothelial Carcinoma (Ia/mUC)	Lucie Meynard, Derek Dinart, Aude Fléchon, Carolina Saldana, Félix Lefort, Gwenaëlle Gravis, Antoine Thiery-Vuillemin, Mathilde Cancel, Elodie Coquan, Sylvain Ladoire, Denis Maillet, Frédéric Rolland, Elouen Boughalem, Sophie Martin, Mathieu Laramas, Laurence Crouzet, Baptiste Abbar, Sabrina Falkowski, Damien Pouessel, Guilhem Roubaud	ASCO GU
Poster	Baseline peripheral cytokines predict survival in metastatic clear cell renal carcinoma (RCC) treated with nivolumab:NIVOREN GETUG-AFU 26 Translational study.	L. Carril-Ajuria, M. Naigeon, C. Dalban, A. Desnoyer, N. Rioux-Leclercq, C Sautès-Fridman, Maxime Meylan, Y. Vano, B. Beusenlick, S. Chouaib, C. de Oliveira, F. Tantot, B. Escudier, N. L. Albiges, N. Chaput.	ASCO GU
Poster	EFFICACY AND SAFETY OF NIVOLUMAB IN BONE METASTASES FROM RENAL CELL CARCINOMA: RESULTS OF THE GETUG — AFU 26 NIVOREN MULTICENTER PHASE II STUDY.	Authors: Maud VELEV(1), Cécile DALBAN (2), Christine CHEVREAU(3), Gwenaëlle GRAVIS(4), Sylvie NEGRIER(2), Brigitte LAGUERRE(5), Marine GROSS-GOUPIL(6), Sylvain LADORE(7), Victoria FERRARI (8), Lionnel GEOFFROIS (9), Hubert Curcio(10), Frank PRIOU(11), Quentin THOMAS (12), Cécile MIONE(13), Philippe BARTHELEMY(14), Florence TANTOT(15), Bernard Escudier(16), Sylvie CHABAUD(2), Lanrence ALBIGES(16), Constance THIBAUT(1).	ASCO GU
Poster	Adrenal metastases are associated with poor outcomes in patients with metastatic clear cell renal cell carcinoma treated with nivolumab in the GETUG-AFU-26 NIVOREN phase II trial.	Emilien Billon , Cécile Dalban, Stéphane Oudard , Christine Chevreau, Brigitte Laguerre , Philippe Barthelemy, Delphine Borchiellini, Lionnel Geoffrois, Remy Delva, Sylvie Negrier, Florence Joly, Antoine Thiery-Vuillemin , Marine Gross-Goupil, Frederic Rolland, Franck Priou, Florence Tantot F, Bernard Escudier, Sylvie Chabaud, Laurence Albiges , Gwenaëlle Gravis.	ASCO GU
Poster	Randomized phase II study to assess the efficacy and tolerability of sunitinib by dose administration regimen in anti-angiogenic naïve patients with metastatic renal cell carcinoma (mRCC): Final analysis of SURF study.	Antoine Thiery-Vuillemin, Gwenaëlle Gravis, Friederike Schlürmann, Emmanuelle Bompas, Frederic Rolland, Marine Gross-Goupil, Yann-Alexandre Vano, Aline Guillot, Philippe Barthélémy, Charlotte Joly, Mathieu Laramas, Louis-Marie Dourthe, Tristan Maurina, Héléne Gauthier, Kristell Taillandy, Aurelia Meurisse, Dewi Vernerey, Laurence Albiges	ASCO GU
Poster	"Outcomes according to histological variants of urothelial carcinoma after neoadjuvant chemotherapy in the GETUG-AFU V05 VESPER trial"	1Yves Allory, 2Stephane Culine, 1Clémentine Krucker, 3Valentin Harter, 4Christian Pfister, VESPER Trial Investigators	ASCO GU
Poster	COMBOPS2: Efficacy of first-line combination therapy in metastatic renal cell carcinoma (mRCC) patients with poor performance status (PS)	Lucía Carril-Ajuria1, Emeline Colomba1, Carmen Romero-Ferreiro2, Luigi Cerbone1, Raffaele Ratta3, Philippe Barthelemy4, Clarisse Vindry5, François Cherifi6, Elouen Boughalem7, Claude Linassier8, Giuseppe Fornarini9, Marine Gross-Goupil10, Carolina Saldana11, Maricruz Martin-Soberón12, Guillermo de Velasco12, Cristina Pernaut13 , Carolina Alves-Costa1, Ronan Flippot1, Bernard Escudier1, Laurence Albiges1	ASCO GU
Presentation orale	GETUG-AFU 22 Phase II Randomized Trial Evaluating Outcomes of Post-Operative Immediate Salvage Radiation Therapy with or without ADT for Patients with Persistently Elevated PSA Level.	Authors: I. Latorzeff, S. Guerif, F. Castan, E. Meyer, S. Supiot, E. Lagneau, E. Deniaud-Alexandre, P. Ronchin, A. Benyoucef, L. Cartier, H. Hamidou, G. Crehange, P. Pommier, N. Magne, M. Zibouche, E. Gross, G. Ploussard, L. Salomon, P. Sargos	ASCO GU
Poster	Baseline levels of proinflammatory cytokines according to body mass index (BMI) and BMI impact on clinical outcomes in metastatic renal cell carcinoma (mRCC) patients treated with nivolumab (NIVO) within the NIVOREN	Emeline Colomba, Lucia Carril-Ajuria, Cécile Dalban, Lisa Derosa, Carolina Alves Costa Silva, Elie Rassy, Sylvie Negrier, Christine Chevreau, Gwenaëlle Gravis, Stephane Oudard, Brigitte Laguerre, Delphine Borchiellini, Philippe Barthelemy, Marine Gross Goupil, Lionnel Geoffrois, Frederic Rolland, Antoine Thiery-Vuillemin, Florence Joly, Sylvain Ladoire, Florence Tantot, Bernard Escudier, Nathalie Chaput, Laurence Albiges	ASCO GU
Poster	Baseline peripheral cytokines predict survival in metastatic clear cell renal carcinoma (RCC) treated with nivolumab: NIVOREN GETUG-AFU 26 Translational study	L. Carril-Ajuria, M. Naigeon, C. Dalban, A. Desnoyer, N. Rioux-Leclercq, C Sautès-Fridman, Maxime Meylan, Y. Vano, B. Beusenlick, S. Chouaib, C. de Oliveira, F. Tantot, B. Escudier, N. L. Albiges, N. Chaput.	ASCO GU

Poster	EFFICACY AND SAFETY OF NIVOLUMAB IN BONE METASTASES FROM RENAL CELL CARCINOMA: RESULTS OF THE GETUG — AFU 26 NIVOREN MULTICENTER PHASE II STUDY.	Maud VELEV, Cécile DALBAN , Christine CHEVREAU, Gwenaëlle GRAVIS, Sylvie NEGRIER, Brigitte LAGUERRE, Marine GROSS-GOUPIL, Sylvain LADOIRE, Victoria FERRARI , Lionnel GEOFFROIS , Hubert Curcio, Frank PRIOU, Quentin THOMAS , Cécile MIONE, Philippe BARTHELEMY, Florence TANTOT, Bernard Escudier, Sylvie CHABAUD, Lanrence ALBIGES, Constance THIBAUT.	ASCO GU
Poster	Adrenal metastases are associated with poor outcomes in patients with metastatic clear cell renal cell carcinoma treated with nivolumab in the GETUG-AFU-26 NIVOREN phase II trial.	Emilien Billon , Cécile Dalban, Stéphane Oudard , Christine Chevreau, Brigitte Laguerre, , Philippe Barthelemy, Delphine Borchiellini, Lionnel Geoffrois, Remy Delva, Sylvie Negrier, Florence Joly, Antoine Thiery-Vuillemin , Marine Gross-Goupil, Frederic Rolland, Franck Priou, Florence Tantot F, Bernard Escudier, Sylvie Chabaud, Laurence Albiges , Gwenaëlle Gravis.	ASCO GU
Poster	Baseline levels of proinflammatory cytokines according to body mass index (BMI) and BMI impact on clinical outcomes in metastatic renal cell carcinoma (mRCC) patients treated with nivolumab (NIVO) within the NIVOREN GETUG-AFU 26	Emeline Colomba, Lucia Carril-Ajuria, Cécile Dalban, Lisa Derosa, Carolina Alves Costa Silva, Elie Rassy, Sylvie Negrier, Christine Chevreau, Gwenaëlle Gravis, Stephane Oudard, Brigitte Laguerre, Delphine Borchiellini, Philippe Barthelemy, Marine Gross Goupil, Lionnel Geoffrois, Frederic Rolland, Antoine Thiery-Vuillemin, Florence Joly, Sylvain Ladoire, Florence Tantot, Bernard Escudier, Nathalie Chaput, Laurence Albiges	ESMO
Poster	abstract 2514 for PEACE1, ESMO 2022: Effect of abiraterone-prednisone in metastatic castration-sensitive prostate cancer (mCSPC) with neuroendocrine and very high-risk features in the PEACE-1 trial.	Authors: A. Bernard-Tessier ¹ , M. Cancel ² , B. Tombal ³ , G. Roubaud ⁴ , J. Carles Galceran ⁵ , A. Flechon ⁶ , R.S., McDermott ⁷ , S. Supiot ⁸ , D. Berthold , , R. Philippe ¹⁰ , G. Kacso ¹¹ , G. Gravis Mescam ¹² , F. Calabro ¹³ , J. Berdah ¹⁴ ,	ESMO
Présentation orale	Abstract 3438 for PEACE1, ESMO 2022: 8-month PSA strongly predicts outcomes of men with metastatic castration-sensitive prostate cancer in the PEACE-1 phase 3 trial.	G. Gravis Mescam ¹ , X. Maldonado ² , G. Roubaud ³ , R.S. McDermott ⁴ , A. Flechon ⁵ , B. Tombal ⁶ , S., Supiot ⁷ , D. Berthold ⁸ , R. Philippe ⁹ , G. Kacso ¹⁰ , F. Calabro ¹¹ , J.F. Berdah ¹² , A. Hasbini ¹³ , M. Silva ¹⁴ , A. Thiery-Vuillemin ¹⁵ ,	ESMO
Présentation orale	GETUG-AFU 22 Phase II Randomized Trial Evaluating Outcomes of Post-Operative Immediate Salvage Radiation Therapy with or without ADT for Patients with Persistently Elevated PSA Level	I. Latorzeff, S. Guerif, F. Castan, E. Meyer, S. Supiot, E. Lagneau, E. Deniaud-Alexandre, P. Ronchin, A. Benyoucef, L. Cartier, H. Hamidou, G. Crehange, P. Pommier, N. Magne, M. Zibouche, E. Gross, G. Ploussard, L. Salomon, P. Sargos	ASTRO
Présentation orale	Radiotherapy quality assurance of the PEACE-1 trial: Initial results of individual case reviews	Najlaa Alyamani ¹ , Paul Sargos ² , Pierre Blanchard ³ , Stephane Supiot ⁴ , Philipe Ronchin ⁵ , Pascal Pommier ⁶ , Thomas Duberge ⁷ , Marlon Silva ⁸ , Yasser Hammoud ⁹ , Ali Hasbini ¹⁰ , Jonathan Khalifa ¹¹ , Khemara Gnep ¹² , Christopher Scrase ¹³ , Jordi Saez ¹⁴ , Laure Vieillevine ¹⁵ , Melissa Christiaens ¹⁶ , Thomas Zilli ¹⁷ , Hélène Ribault ¹⁸ , Alberto Bossi ¹⁹ , Karim Fizazi ²⁰ , Nicolaus Andratschke ²	ESTRO